BioSpace News Archive

Carisma Therapeutics Inc. today announced the appointment of Eugene P. Kennedy, M.D., F.A.C.S. as the Company’s Chief Medical Officer.

Palatin Technologies, Inc. today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the investigational new drug (IND) application for the use of bremelanotide, a melanocortin receptor 4 agonist (MCR4), for the treatment of obesity.

Organon (NYSE: OGN) today announced its results for the first quarter ended March 31, 2024.

Lantern Pharma Inc. today announced that it will host its first quarter 2024 financial results webcast on Thursday, May 9, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced results for its first quarter ended March 31, 2024.

Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc., announced the peer-reviewed publication of positive data from a National Cancer Institute -sponsored, prospective, multicenter clinical validation study assessing the performance of Lucid’s EsoGuard® Esophageal DNA Test on samples collected with its EsoCheck® Esophageal Cell Collection Device.

EDAP TMS SA, the global leader in robotic energy-based therapies, announced that it will release its financial results for the first quarter ended March 31, 2024, before the markets open on Thursday, May 16th, 2024.

Allarity Therapeutics, Inc. announced the early discontinuation of its Phase 2 clinical trial of stenoparib, a novel PARP inhibitor, for the treatment of advanced recurrent ovarian cancer.

STALICLA SA announces the First Patient First Visit for the company’s drug-drug interaction study of STP7, an mGluR5 negative allosteric modulator, licensed to STALICLA by Novartis.

Mersana Therapeutics, Inc. announced that it will provide business updates and report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024.